Organon & Co.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
Contents
Restructuring
- Restructuring
During the first quarter of 2026, the Company implemented restructuring initiatives that will result in an approximate 3% headcount reduction, to streamline and optimize the Company's research and development and manufacturing operations, focusing on enhancing efficiency and aligning resources with strategic priorities. The Restructuring costs primarily consist of employee termination benefits and other associated expenses.
During the first quarter of 2025, the Company implemented restructuring initiatives to drive an enterprise-wide operating model optimization that resulted in an approximate 6% headcount reduction. The restructuring activities were initiated to streamline and simplify the Company’s operating model to create more efficient processes and a simplified structure. Restructuring costs include separation costs associated with manufacturing-related headcount reductions.
The following is a summary of changes in severance liabilities related to the restructuring activities included within Accrued and other current liabilities:
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Beginning balance | $8 | $14 |
| Severance & severance related costs | 31 | 95 |
| Cash payments and other | (7) | (101) |
| Ending balance | $32 | $8 |
Organon expects the remaining severance payments associated with the restructuring activities to be paid within the next twelve months.
-13-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.